Owkin's startup Waiv spends $33 million to bring AI precision to cancer decision-making

Waiv was formerly the diagnostics division of AI biotech Owkin, where it developed AI testing technology and applied it in clinical settings and cancer drug research. Co-founder and CEO Meriem Sefta said the spin-off into an independent company allows Waiv to pursue its own growth strategy.

This article about Owkin's $33 million startup Waiv, which aims to bring artificial intelligence precision to cancer decision-making, first appeared on MedCity News.